Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125552081 | 12555208 | 1 | I | 20160629 | 20160714 | 20160714 | EXP | US-CIPLA LTD.-2016US09522 | CIPLA | EILERS B, ALBERS E, LAW Y, MIKE MCMULLAN D, SHAW D, KEMNA M.. POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AFTER PEDIATRIC HEART TRANSPLANTATION: INCREASED RISK FOR CHILDREN WITH PREEXISTING GLENN/FONTAN PHYSIOLOGY.. PEDIATRIC TRANSPLANTATION. 2016;20 (4):552 TO 558 | 0.00 | Y | 0.00000 | 20160714 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125552081 | 12555208 | 1 | PS | LEVETIRACETAM. | LEVETIRACETAM | 1 | Unknown | UNK | U | U | 78234 | ||||||||
| 125552081 | 12555208 | 2 | SS | LORAZEPAM. | LORAZEPAM | 1 | Unknown | UNK | U | U | 0 |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125552081 | 12555208 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125552081 | 12555208 | Posterior reversible encephalopathy syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |